An interventional study of Biofeedback Training in Glaucoma and Biofeedback Training, sponsored by University Health Network, Toronto. Recruiting at 1 site in Canada. Per ClinicalTrials.gov, last updated 2026-02-13.
Sponsored by University Health Network, Toronto · Not applicable, Interventional, and Supportive care
How we know · 2 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 85 studies in Glaucoma with a site in Canada — 17 open to participants now, 21 under way, 1 of them phase 3. Glaucoma · Canada.
Among the 85 studies in Glaucoma with a site in Canada, this one is the 29th largest by planned enrollment of the 68 interventional ones that give a count, is one of 5 that started in 2026, is one of 43 with no phase, reaches primary completion later than 17 of the 20 other live ones, and was the 83rd registered.
1,421 studies on the registry are indexed under Glaucoma; 221 are open to participants now.
Browse Glaucoma studies →17 of the 85 studies in Glaucoma with a site in Canada are open now. Recruiting first, the newest first:
University of Waterloo · Sites in Canada
Ages 18+
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18+
Nova Scotia Health Authority · Sites in Canada
Ages 18+
University of Pennsylvania · Sites in Canada, United States
Ages 18+
Centre hospitalier de l'Université de Montréal (CHUM) · Sites in Canada
Ages 18–80
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
85 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 2 · Phase 3 8 · Phase 4 14
First in 1995; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 70 is above the median of 61 across 965 interventional studies indexed under Glaucoma.
Median enrollment 62 across the 68 interventional studies, 84 across the 15 observational. Of the 46 that completed or were terminated, 13 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 85 have an industry lead sponsor. The 10 most frequent:
University Health Network, Toronto is the lead sponsor of 1,441 studies on the registry; 298 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 3 (18%) have results posted.
University Health Network, Toronto has 7 studies filed under Glaucoma — fewer than ten, so there is no comparison to draw.
7 of the studies in Glaucoma with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04967989Phase 3University of PittsburghClarifying the Optimal Application of SLT Therapy Trial | 2027-06-30 |
| NCT05924477University of PennsylvaniaGlaucoma Drainage Device and Endothelial Cell Loss Compare Trial | 2026-12 |
| NCT05180994Centre hospitalier de l'Université de Montréal (CHUM)Topical Infliximab in Eyes With Penetrating Keratoplasty | 2027-03-01 |
| NCT05024695iSTAR MedicalEvaluate the Safety and Effectiveness of iSTAR Medical's MINIject™ Implant for Lowering Intraocular Pressure (IOP) in Subjects With Primary Open-angle Glaucoma. | 2027-07 |
| NCT07739784McGill University Health Centre/Research Institute of the McGill University Health CentreThis Study Examines Whether Personality Traits Influence the Frequency or Severity of Ocular Adverse Effects Reported by Patients Using Glaucoma Medications. The Findings May Identify Patients at Greater Risk of Intolerance and Support More Personalized Treatment and Counselling. | 2027-07-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 85 studies in Glaucoma with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized controlled clinical trial evaluates the efficacy of visual biofeedback training on visual function and quality of life in individuals with glaucoma. Glaucoma is a progressive optic neuropathy that can lead to irreversible vision loss, including impaired fixation stability, reduced retinal sensitivity, and decreased functional vision. Biofeedback training is a visual rehabilitation technique designed to help patients improve fixation stability and optimize use of remaining visual function by training eye movements toward retinal areas with better sensitivity.
Seventy participants with glaucoma will be randomized to either a biofeedback training intervention group or a control group. Visual function outcomes, including fixation stability, retinal sensitivity, visual acuity, reading speed, contrast sensitivity, and quality of life, will be assessed at baseline and follow-up visits. This study aims to determine whether biofeedback training can improve visual function and quality of life in patients with glaucoma.
Glaucoma is a leading cause of irreversible blindness worldwide and is characterized by progressive damage to the optic nerve, resulting in visual field loss, impaired fixation stability, and reduced retinal sensitivity. In advanced stages, patients may develop unstable or eccentric fixation, leading to significant functional visual impairment and reduced quality of life. Current glaucoma treatments primarily aim to control intraocular pressure and do not address the rehabilitation of visual function once damage has occurred.
This prospective, randomized controlled trial is designed to evaluate the efficacy of visual biofeedback training (BT) as a rehabilitation strategy for improving visual function and quality of life in individuals with glaucoma. Biofeedback training is a non-invasive intervention that uses visual and auditory feedback to guide participants in directing their eye movements toward a preferred retinal locus with better sensitivity and stability, thereby optimizing the use of residual vision.
A total of 70 participants with a prior diagnosis of glaucoma will be enrolled and randomized in a 1:1 ratio to either the biofeedback training group (n=35) or a control group (n=35). Participants in the intervention group will undergo five weekly sessions of biofeedback training, each lasting approximately 20 minutes. Participants in the control group will receive standard clinical assessments and will be offered biofeedback training after completion of the control period.
Primary outcome measures include fixation stability and retinal sensitivity assessed using microperimetry, best-corrected visual acuity for distance and near vision, reading speed, and vision-related quality of life. Secondary outcome measures include preferred retinal locus characteristics, contrast sensitivity, oculomotor function (saccades and smooth pursuit), visual field testing, and optical coherence tomography parameters.
Assessments will be conducted at baseline and at follow-up visits, including 9 weeks, 6 months, 1 year, and up to 2 years post-intervention for the treatment group. Data analysis will be conducted using an intention-to-treat approach. This study seeks to determine whether visual biofeedback training can improve functional vision and quality of life in individuals with glaucoma and to explore whether treatment effects vary by age and baseline retinal sensitivity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants randomized to this arm will receive visual biofeedback training in addition to standard clinical care. The intervention consists of five weekly in-office training sessions, each lasting approximately 20 minutes. During training, participants are guided using visual and auditory feedback to direct eye movements toward a preferred retinal locus with better retinal sensitivity and fixation stability. Visual function and quality of life assessments will be conducted at baseline and at scheduled follow-up visits.
Other: Biofeedback Training
Participants randomized to this arm will undergo standard clinical assessments without biofeedback training during the initial study period. Visual function and quality of life assessments will be conducted at baseline and at the 9-week follow-up visit. After completion of the control period, participants will be offered biofeedback training as part of standard clinical care.
Other: Biofeedback Training
Visual Biofeedback Training
Quality of Life Questionnaire
Quality of Life using the MAssof 48 questions validated questionnaire
Time frame: Baseline, 9 weeks, 6 months, 1 year and 2 years.
Visual acuity
Distance visual acuity measured with ETDRS charts at 4 meters
Time frame: Baseline and follow-up visits at 9 weeks, 6 months, 1 year, and 2 years post-intervention
Fixation Stability
Measured with the MP3 MICROPERIMETER
Time frame: Baseline, 9 weeks, 6 months, 1 year and 2 years.
Near Vision
Measured with the Colenbrander charts at 100% contrast in ETDRS logMAR.
Time frame: Baseline, 9 weeks, 6 months, 1 year and 2 years.
Reading speed
Measured with the MNRead App
Time frame: Baseline, 9 weeks, 6 months, 1 year and 2 years.
Contrast Sensitivity
Measured with the VCTS charts.
Time frame: Baseline, 9 weeks, 6 months, 1 year and 2 years.
Retinal Sensitivity
Measured with the Nidek MP3 microperimeter
Time frame: Baseline, 9 weeks, 6 months, 1 year and 2 years.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Started Feb 2026 (actual). Primary completion is estimated for Jan 2028, 23 months after the start.
Of 230 non-industry interventional studies with no phase under Glaucoma, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 55. This study's planned 23 months is below that.
Counting every sponsor, half of 288 studies reached it within 30 months; a quarter within 12 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Health Network, Toronto →